Rituximab has never been investigated in MRD persistence/relapse. We describe a clinical picture of a woman with Ph-negative B-ALL CD20+, ineligible to allogeneic transplant, achieving MRD eradication using rituximab monotherapy after frontline chemotherapy and blinatumomab failure. This demonstrates rituximab’s potential in MRD+ Ph-negative B-ALL CD20+, warranting further clinical investigation.
Rituximab efficacy for minimal residual disease eradication in philadelphia-negative acute lymphoblastic leukemia CD20+ / N. Cecchi, M.S.. - In: ANNALS OF HEMATOLOGY. - ISSN 0939-5555. - 104:6(2025), pp. 3523-3526. [10.1007/s00277-025-06332-y]
Rituximab efficacy for minimal residual disease eradication in philadelphia-negative acute lymphoblastic leukemia CD20+
F. Passamonti;
2025
Abstract
Rituximab has never been investigated in MRD persistence/relapse. We describe a clinical picture of a woman with Ph-negative B-ALL CD20+, ineligible to allogeneic transplant, achieving MRD eradication using rituximab monotherapy after frontline chemotherapy and blinatumomab failure. This demonstrates rituximab’s potential in MRD+ Ph-negative B-ALL CD20+, warranting further clinical investigation.
| File | Dimensione | Formato | |
|---|---|---|---|
|
unpaywall-bitstream--767929472.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Licenza:
Creative commons
Dimensione
781.63 kB
Formato
Adobe PDF
|
781.63 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
